Trastuzumab deruxtecan (T-DXd) maintains clinical effectiveness for patients with HER2-low metastatic breast cancer in community oncology settings, according to a recent retrospective analysis of ONCare Alliance electronic health records. The study of 300 patients found a median real-world progression-free survival (rwPFS) of 7.4 months, demonstrating that the drug performs reliably even in populations that are older and more heavily pretreated than those typically included in clinical trials.
How does real-world performance compare to clinical trials?
Real-world data often reveals a more complex patient profile than controlled clinical studies. According to the ONCare Alliance analysis, the median age of the cohort was 65 years, with 22.7% of patients presenting with an ECOG performance status of 2 or higher. Despite this, the treatment yielded a real-world overall response rate of 56.3%. This suggests that T-DXd remains a viable therapeutic option for “frailer” patients who might have been excluded from initial registration trials due to stringent eligibility criteria.
Why does hormone receptor (HR) status matter for treatment timing?
Treatment patterns differ significantly based on hormone receptor status, according to the research data. While baseline characteristics remained largely consistent across the cohort, HR-positive patients were more likely to receive T-DXd in later lines of therapy. Specifically, 88.7% of HR-positive patients received the drug as a third-line treatment or later, compared to 53.6% of HR-negative patients. This variance highlights a tendency to exhaust endocrine-based or other systemic therapies in HR-positive cases before initiating T-DXd.
What is the impact of brain metastases on patient outcomes?
The presence of brain metastases did not result in a statistically significant difference in progression-free survival in this community-based cohort. Researchers reported that patients with brain metastases experienced a median rwPFS of 6.3 months, compared to 7.5 months for those without (P = .07). While the numbers were numerically lower for the brain metastases group, the lack of a stark statistical divide suggests that T-DXd may still offer meaningful benefit in this subset of patients, aligning with broader oncological efforts to manage central nervous system involvement more effectively.
Did you know? Roughly 24.7% of the study participants were diagnosed with de novo metastatic breast cancer, meaning the cancer had already spread at the time of their initial diagnosis.
Frequently Asked Questions
What was the primary goal of this real-world study?
The study aimed to evaluate treatment patterns and effectiveness of T-DXd in community oncology clinics, where patient populations are often more diverse and have more comorbidities than those in academic research centers.
How long did patients typically remain on treatment without progression?
The median real-world progression-free survival (rwPFS) was 7.4 months across the entire study population.
Is T-DXd effective for patients with comorbidities?
Yes. With 39.3% of the study group having one or more comorbidities, the results indicate that the treatment is effective across a broader, more representative patient demographic than previously documented.
Are you a healthcare provider or patient interested in the latest oncology treatment data? Subscribe to our newsletter for regular updates on clinical research and real-world evidence in cancer care.
Keep reading